Gaia has closed a $100M debt facility from Viola Credit to expand its outcome-based fertility financing model nationwide. Using AI and machine learning, Gaia personalises financing plans based on predicted treatment success - flipping the traditional fee-for-service model so patients have financial protection if treatment doesn't work. The company already has 1,100+ memberships and partnerships with 200 clinics across 40 states. The raise follows a $14M Series A.
“We are not just a financing company, we use data in order to create unique plans that are individualized with outcome protections built in. We tell you where to go, we protect your path, we finance your treatment, we support you. No one else today bundles care, capital and financial protection into a single product.”
— Nader Al Salim, Founder & CEO, Gaia
🔗 https://news.crunchbase.com/health-wellness-biotech/ivf-startup-ai-fertility-probability-gaia/
The Finnish smart ring maker has submitted draft paperwork to the SEC for a US IPO, following a late 2025 funding round that valued the business at around $11 billion - more than double its 2024 valuation. CEO Tom Hale has projected $2 billion in annual revenue for 2026, up from $500M just two years ago, with 5.5M+ rings sold and the company on pace to surpass 5 million paid subscribers. Oura has been pushing further into women's health and AI-powered coaching, with a subscription-based health platform at the core of its IPO pitch.
Sydney-based Factory Capital has launched a USD$18M commitment to 5-10 Australian start-ups, launching with the Institute Advancing Women's Health (InAWH), a new Austin-based nonprofit developing treatment protocols, care pathways and clinician training for peri- and post-menopause care.
“What we’re really doing is creating a market – helping women achieve improved midlife health by building an investable category.”
— Anna Samuelsson, Managing Director & Partner, Factory Capital
Oli's wireless wearable monitors maternal and foetal signals and aims to predict up to 15 conditions across pregnancy and birth - including postpartum haemorrhage, foetal distress and stillbirth risk. The Series A3 round, backed by Scale Investors, Clare Ventures and the University of Sydney, brings total private capital raised to $13M, alongside $9.5M in non-dilutive grants. Pivotal clinical trials are underway across seven sites in Australia and the US, with TGA and FDA submissions in progress.
The AI-enabled cervical cancer screening company has completed an oversubscribed share placement, securing firm commitments for ~130 million shares at NZ$0.014 per share. A renounceable rights issue opens May 29 to allow existing shareholders to participate. The raise supports TruScreen's distributor-led expansion, which their management describes as potentially transformational.
Ahead of Menstrual Health Day on May 28, Shoppers Foundation for Women's Health has announced $150,000 each over two years to Moon Time Connections - Canada's only national Indigenous-led menstrual equity organisation - and Help a Girl Out, a charity focused on menstrual and uterine health education. The commitment builds on $2.3M donated to 24 organisations since 2022.
“Menstrual equity is about more than access to products, it’s about dignity, education, health, and ensuring people can fully participate in school, work and everyday life. Through partnerships with organizations like Moon Time Connections and Help a Girl Out, we’re expanding access to education, community support, and essential menstrual care for people across Canada.”
— Paulette Minard, Director of Community Investment and Shoppers Foundation for Women’s Health
